Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MLYS Mineralys Therapeutics	$14.92 -4.1%	$14.63	$8.24 ▼ $18.38	$1.01B	-0.17	506,917 shs	725,134 shs
PVLA Palvella Therapeutics	$26.42 +4.3%	$23.67	$6.20 ▼ $29.27	$292.10M	-0.1	69,380 shs	66,022 shs
RCUS Arcus Biosciences	$9.37 +3.2%	$8.59	$6.50 ▼ $18.98	$992.14M	0.83	881,860 shs	2.86 million shs
WVE Wave Life Sciences	$7.20 +0.1%	$6.49	$4.25 ▼ $16.74	$1.11B	-1.04	1.32 million shs	778,543 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MLYS Mineralys Therapeutics	-2.99%	+0.19%	+3.60%	+15.19%	+19.71%
PVLA Palvella Therapeutics	-3.47%	+6.34%	+22.02%	-6.84%	+2,531,999,900.00%
RCUS Arcus Biosciences	-9.47%	-5.27%	+3.06%	-5.02%	-41.91%
WVE Wave Life Sciences	-0.55%	+7.63%	+8.94%	-29.99%	+15.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MLYS Mineralys Therapeutics	3.0546 of 5 stars	3.4	3.0	0.0	2.2	5.0	0.0
PVLA Palvella Therapeutics	4.0465 of 5 stars	4.6	0.0	0.0	3.0	4.2	0.6
RCUS Arcus Biosciences	2.558 of 5 stars	4.5	0.0	0.0	2.6	2.5	0.0
WVE Wave Life Sciences	4.4445 of 5 stars	3.5	1.0	4.8	3.4	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	116.15% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	75.19% Upside
RCUS Arcus Biosciences	2.90	Moderate Buy	$24.13	157.47% Upside
WVE Wave Life Sciences	2.92	Moderate Buy	$20.50	184.72% Upside

Current Analyst Ratings Breakdown

Latest PVLA, WVE, RCUS, and MLYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	WVE Wave Life Sciences	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$14.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/29/2025	WVE Wave Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$10.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
PVLA Palvella Therapeutics	$42.81M	6.82	N/A	N/A	$21.66 per share	1.22
RCUS Arcus Biosciences	$141M	7.04	N/A	N/A	$6.17 per share	1.52
WVE Wave Life Sciences	$104.94M	10.58	N/A	N/A	$0.40 per share	18.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-67.97%	-62.40%	8/12/2025 (Estimated)
PVLA Palvella Therapeutics	-$24.54M	-$12.10	N/A	N/A	N/A	N/A	-80.93%	-59.55%	8/13/2025 (Estimated)
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	8/4/2025 (Estimated)
WVE Wave Life Sciences	-$57.51M	-$0.84	N/A	N/A	N/A	-66.50%	-280.57%	-52.90%	8/6/2025 (Estimated)

Latest PVLA, WVE, RCUS, and MLYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	WVE Wave Life Sciences	-$0.27	-$0.29	-$0.02	-$0.29	$11.65 million	$9.18 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
WVE Wave Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MLYS Mineralys Therapeutics	N/A	14.02	14.02
PVLA Palvella Therapeutics	N/A	4.82	4.82
RCUS Arcus Biosciences	0.08	5.24	5.24
WVE Wave Life Sciences	N/A	1.90	1.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MLYS Mineralys Therapeutics	84.46%
PVLA Palvella Therapeutics	40.11%
RCUS Arcus Biosciences	92.89%
WVE Wave Life Sciences	89.73%

Insider Ownership

Company	Insider Ownership
MLYS Mineralys Therapeutics	25.56%
PVLA Palvella Therapeutics	20.50%
RCUS Arcus Biosciences	12.30%
WVE Wave Life Sciences	29.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	33.27 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	10.50 million	N/A
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
WVE Wave Life Sciences	240	154.13 million	108.14 million	Optionable

PVLA, WVE, RCUS, and MLYS Headlines

Recent News About These Companies

Wave Life Sciences (NASDAQ:WVE) Coverage Initiated by Analysts at Raymond James

June 12 at 3:57 AM | americanbankingnews.com

Cantor Fitzgerald Comments on WVE FY2026 Earnings

June 12 at 2:23 AM | americanbankingnews.com

Wave Life Sciences (NASDAQ:WVE) Now Covered by Raymond James

June 11 at 10:17 AM | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Receives Average Recommendation of "Buy" from Analysts

June 11 at 2:23 AM | marketbeat.com

Brokers Offer Predictions for WVE FY2026 Earnings

June 10 at 8:29 AM | marketbeat.com

Wave Life Sciences (NASDAQ:WVE) Shares Down 4.6% - Here's Why

June 9 at 1:18 PM | marketbeat.com

Two Sigma Advisers LP Buys Shares of 68,100 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 3, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 362,291 Wave Life Sciences Ltd. (NASDAQ:WVE)

June 2, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $6.85 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 31, 2025 | marketbeat.com

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Two Sigma Investments LP

May 29, 2025 | marketbeat.com

Bank of America Corp DE Acquires 160,820 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE)

May 29, 2025 | marketbeat.com

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 28, 2025 | globenewswire.com

Polar Asset Management Partners Inc. Has $6.89 Million Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 28, 2025 | marketbeat.com

845,830 Shares in Wave Life Sciences Ltd. (NASDAQ:WVE) Purchased by Voloridge Investment Management LLC

May 27, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Lifted by Millennium Management LLC

May 25, 2025 | marketbeat.com

BNP Paribas Financial Markets Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 20, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Holdings Increased by Northern Trust Corp

May 19, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Buy" by Analysts

May 19, 2025 | marketbeat.com

Polar Capital Holdings Plc Acquires New Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

May 18, 2025 | marketbeat.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Bought by D. E. Shaw & Co. Inc.

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, WVE, RCUS, and MLYS Company Descriptions

Mineralys Therapeutics NASDAQ:MLYS

$14.92 -0.63 (-4.05%)

As of 04:00 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Palvella Therapeutics NASDAQ:PVLA

$26.42 +1.10 (+4.34%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Arcus Biosciences NYSE:RCUS

$9.37 +0.29 (+3.19%)

As of 03:58 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Wave Life Sciences NASDAQ:WVE

$7.20 +0.01 (+0.14%)

As of 04:00 PM Eastern

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time